Atopic dermatitis and debilitating eczema affect millions worldwide with no concrete treatment. A team of researchers from the Mount Sinai School of Medicine has now published promising results of rocatinlimab, a novel, patient-tailored monoclonal antibody therapy to treat atopic dermatitis. The drug was assessed in a phase 2b multicenter, double-blind, placebo-controlled clinical trial involving 272 participants. The findings have been published in The Lancet.
Rocatinlimab inhibits OX40, an immune molecule that activates inflammatory cells in atopic dermatitis and other inflammatory diseases. Patients with moderate to severe atopic dermatitis were reported to sustain significant improvement in signs and symptoms up to 20 weeks after discontinuing the medication. Rocatinlimab exhibited a long-term ability to change the genetic makeup of a person’s atopic dermatitis to produce…
